Drug firm Lupin on Monday said the US health regulator has completed inspection of its Aurangabad facility in Maharashtra without any observation. The inspection was carried out by the United States Food and Drug Administration (USFDA) between February 10 to 14, 2020, Lupin said in a filing to the BSE. The inspection concluded without any observation, it added. "We are encouraged with the successful inspection at our Aurangabad facility. We continue to enhance our standards of quality and compliance across our manufacturing operations and remain committed to uphold the highest quality standards across all our sites," Lupin MD Nilesh Gupta said. Shares of Lupin on Monday closed 1.03 per cent lower at Rs 710.45 per scrip on the BSE.